Want to see URGN full AI Analyst Report?
URGN Stock Chart & Stats
$46.36
$0.54(1.32%)
At close: 4:00 PM EDT
$46.36
$0.54(1.32%)
Day’s Range― - ―
52-Week Range$15.86 - $50.81
Previous CloseN/A
Volume333.78K
Average Volume (3M)700.56K
Market Cap
$1.98B
Enterprise Value$1.94K
Total Cash (Recent Filing)$107.97M
Total Debt (Recent Filing)$196.13M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 05, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding48,880,566
10 Day Avg. Volume773,956
30 Day Avg. Volume700,559
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$60.20Price Target Upside29.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$322.20M
Bulls Say, Bears Say
Bulls Say
ZUSDURI Commercial MomentumZUSDURI is showing strong early commercial traction, with rapid revenue growth, broader account activation, and increasing repeat use. Expanding physician adoption can establish a durable second product franchise, diversify revenue beyond JELMYTO, and improve operating leverage as commercialization scales.
High-margin Product EconomicsVery high gross margins indicate attractive product-level economics and meaningful revenue retained after direct costs. If UroGen can control commercialization and development spending, this gross-profit structure could support future operating leverage and provide a strong foundation for eventual profitability.
Clinical And Intellectual-property DurabilityLong-duration clinical outcomes and expected patent protection into 2044 strengthen the potential durability of UroGen’s uro-oncology franchise. These assets may support sustained physician confidence, defend commercial opportunity, and create time for pipeline products to build on the platform.
Bears Say
Persistent Operating LossesUroGen remains far from operating profitability despite strong gross margins, reflecting a heavy burden from research, development, and commercial spending. Persistent losses reduce internal funding capacity and make successful execution of the launch and pipeline essential to achieving sustainable earnings.
Cash Burn And Rising LeverageMaterial cash consumption combined with increasing debt creates ongoing funding and financial-flexibility risk. Continued burn could require additional financing before profitability, while higher obligations may increase interest costs and limit the resources available for commercial expansion or pipeline development.
Execution Risk From Elevated InvestmentHigher planned operating expenses raise the execution hurdle for converting ZUSDURI’s early adoption into durable profitability. The absence of full-year product guidance also signals limited visibility into demand, leaving results sensitive to adoption pace, commercialization efficiency, and pipeline investment requirements.
Urogen Pharma News
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $15.86 and its highest was $50.81 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $1.98B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 32 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 05, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.015.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.1.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,880,566 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went up 16.308%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.20 (29.85% Upside)
$60.20 (29.85% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 86%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 59.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
URGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong positive momentum driven by the ZUSDURI launch (Q2 ZUSDURI revenue of $50.4M, rapid growth in activated accounts and prescribers, durable Phase III durability data, pipeline progress, favorable IP outcomes and materially higher total revenue). Management acknowledged measured near-term risks including continued operating expense increases, quarter-to-quarter variability, remaining net loss (though substantially improved), and early-stage adoption dynamics. They reinforced confidence in cash sufficiency to reach profitability while accelerating investments to support long-term growth.View all URGN earnings summariesURGN Stock 12 Month Forecast
Average Price Target
$60.20
▲(29.85% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
1.77% Insiders
5.16% Mutual Funds
43.99% Other Institutional Investors
41.55% Public Companies and
Individual Investors